



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	92.08
Trade Time:	4:00 PM ET Apr 26, 2018
Change:	2.88 (3.229%)
Day Range	89.65 - 92.96
52-Week Range	84.25 - 147.17
Volume	6,029,625

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Apr 24, 2018*
[New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting](#)
- Apr 19, 2018*
[Celgene Corporation Announces Changes to Its Board of Directors](#)
- Apr 17, 2018*
[Celgene Corporation to Webcast at Upcoming Investor Conferences](#)
- Apr 9, 2018*
[Celgene Corporation to Announce First Quarter 2018 Results on May 04, 2018](#)
- Apr 2, 2018*
[Celgene Corporation Announces Departure of President and Chief Operating Officer Scott A. Smith](#)

Upcoming Events [\[View all \]](#)

- May 4, 2018 9:00 AM ET*
[Celgene Corporation Q1 2018 Earnings Conference Call](#)
- May 8, 2018 12:50 PM ET*
[Deutsche Bank 43rd Annual Health Care Conference](#)

Financials [\[View all \]](#)

- Feb 7, 2018*
[Annual Report \(10-K\)](#)
- Apr 27, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Oct 26, 2017*
[Quarterly Report \(10-Q\)](#)
- Jul 27, 2017*
[Quarterly Report \(10-Q\)](#)
- Apr 27, 2017*
[Quarterly Report \(10-Q\)](#)